Taking people in DenmarkPhase 4
Treating prediabetes in people with coronary artery disease to restore normal blood sugar
Tests whether glucose-lowering drugs return blood sugar to normal in prediabetes with coronary artery disease.
Key facts
- Who runs it
- Region Midtjylland
- Where
- Aarhus N, DenmarkSee the site
- Trial code
- Registry title
- The REVERT-PREDIABETES trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 158 people, planned
- Started
- 3 Mar 2026
- Expected to end
- 31 Oct 2029
- Type of study
- Interventional
- Record updated
- 23 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease shown on scans, who have prediabetes or normal blood sugar. It tests whether heart-protecting sugar-lowering drugs bring blood sugar back to normal.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Chronic coronary syndrome with documented coronary artery disease. If there was a previous heart attack, at least 30 days must have passed before randomization.
- Earlier treatment
- No current or previous use of diabetes medication.
- Biomarker or test result
- HbA1c 42-47 mmol/mol (6–6.5%) (prediabetes) or HbA1c <39 mmol/mol (5.7%) (normal blood sugar).
Main reasons for not taking part
- eGFR <30 mL/min/1.73 m2
- Heart failure with NYHA class III or IV
- Previous diabetes diagnosis or previous HbA1c >47 mmol/mol (6.5%)
- Anemia, recent bleeding or blood transfusion (<3 months)
- Previous pancreatitis
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Chronic coronary syndrome with documented coronary artery disease. In the case of previous myocardial infarction, at least 30 days between the event and randomization is required
- Prediabetes defined as HbA1c 42-47 mmol/mol OR normoglycemia defined as HbA1c <39 mmol/mol
- Age 18 to 80 years
Who cannot take part
- Previous pancreatitis
- Heart failure with NYHA class III or IV
- Anemia, recent bleeding or blood transfusion (<3 months)
- Known hemoglobinopathy and other conditions with effect on erythrocyte lifespan
- eGFR <30 mL/min/1.73 m2
- Previous diabetes diagnosis, previous HbA1c >47 mmol/mol, or current/previous usage of diabetes medication
- Intake of medications with known effect on HbA1c validity
- Pregnancy, breastfeeding, or fertile women who do not use highly effective birth control
- Strongly reduced liver function
- Chronic alcohol abuse
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
About the trial
What the trial wants to find out
To examine the proportion of patients with angiographically documented coronary artery disease that can be reverted from prediabetes to normoglycemia by using cardioprotective glucose-lowering drugs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial
- Plain-language title
- Treating prediabetes in people with coronary artery disease to restore normal blood sugarGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 23 November 2025